NASDAQ:ESPR - Esperion Therapeutics, Inc.
$40.94
 $0.84
+2.09%
4:00PM EDT
2019-04-18
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ESPR     avg for
industry  
  avg for
sector  
42 stocks weight:  3. 88   203. 85   241. 91  
42 stocks rank:  3. 20 K 1. 44 K 1. 05 K
# analyst opinions:  13. 00   14. 51   13. 97  
mean recommendation:  2. 10   2. 09   2. 01  

quick ratio:  2. 11   5. 27   1. 81  
current ratio:  2. 22   5. 62   2. 25  

target price low:  48. 00   84. 80   115. 21  
target price avg:  85. 54   111. 51   137. 51  
target price high:  48. 70   135. 81   157. 84  
1-yr high:  73. 27   114. 23   138. 78  
last close:  40. 94   87. 66   116. 69  
50-day avg:  44. 58   95. 54   123. 44  
200-day avg:  46. 06   94. 25   121. 11  
1-yr low:  36. 20   72. 78   98. 34  
volume:  855. 43 K 4. 11 M 8. 07 M
50-day avg volume:  550. 33 K 2. 76 M 5. 02 M
200-day avg volume:  648. 95 K 2. 92 M 4. 59 M

1-day return:  2. 09 % -0. 41 % 0. 07 %
this week return:  -0. 80 % -5. 74 % -4. 11 %
12-wk return:  -8. 41 % 1. 61 % -0. 05 %
52-wk return:  -45. 27 % 3. 12 % 8. 78 %

enterprise value (EV):  962. 19 M 48. 94 B 114. 64 B
market cap:  1. 10 B 43. 07 B 104. 73 B
EBITDA:  -204. 32 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -4. 71   4. 22   12. 73  
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -201. 81 M 2. 20 B 4. 20 B

shares outstanding:  26. 82 M 571. 70 M 1. 24 B
shares:  20. 09 M 571. 81 M 1. 23 B
shares short:  4. 64 M 10. 17 M 13. 00 M
shares short prior month:  4. 96 M 9. 54 M 17. 33 M
short ratio:  7. 21   5. 41   3. 28  
total cash/share:  5. 07   11. 14   9. 33  
total cash:  136. 02 M 6. 71 B 7. 15 B
free cash flow:  -74. 46 M 3. 58 B 2. 96 B
operating cash flow:  -148. 64 M 4. 15 B 4. 30 B

book value:  2. 95   12. 78   26. 92  
price/book:  13. 88   3. 06   -1. 74  
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  -35. 11 % --- ---
1-yr mean volatility:  -0. 12 % 0. 03 % 0. 04 %

1-yr EPS:  -7. 54   2. 40   4. 10  
forward EPS:  -2. 40   3. 97   7. 13  
P/E:  -5. 43   13. 63   22. 72  
forward P/E:  -17. 06   -15. 95   13. 99  
PE/G:  0. 45   -1. 65   -1. 32  
growth:  -12. 13 % 127. 12 % 29. 61 %
earnings high:  3. 89   1. 00   1. 66  
earnings avg:  0. 97   0. 77   1. 53  
earnings low:  -2. 11   0. 50   1. 39  
revenue high:  150. 00 M 2. 68 B 10. 78 B
revenue avg:  79. 03 M 2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -60. 70 % -2. 75 % 4. 55 %
return on equity:  -124. 65 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  1. 55   1. 25   0. 93  
sharpe (1yr):  -0. 42   0. 37   0. 70  

held % insiders:  5. 03 % 6. 39 % 3. 38 %
held % institutions:  108. 59 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : ESPR
.        + 0 =             0 :: INITIAL WEIGHT
.   + 48.674 =        48.674 :: inverse volume-to-price addition
.   + 46.445 =        95.119 :: spline projection addition
.    x 1.924 =       183.044 :: 13 weeks' performance factor
.    x 0.723 =       132.369 :: one-year gains+dividend factor
.    x 1.431 =       189.475 :: industry recommendation factor
.    x 2.076 =       393.395 :: symbol recommendation factor
.    x 0.994 =       391.007 :: return on assets factor
.    x 0.988 =       386.133 :: return on equity factor
.    x 2.394 =       924.474 :: current ratio factor
.    x 1.378 =      1273.517 :: quick ratio factor
.    x 1.067 =      1358.966 :: short ratio factor
.    x 2.274 =       3090.23 :: price-to-book factor
.    x 2.079 =      6423.332 :: P/E weight
.    x 1.223 =      7852.908 :: PE/G factor
.    x 1.402 =     11011.663 :: beta factor
.    x 0.425 =      4677.925 :: sharpe factor
.    x 1.426 =      6671.704 :: target low factor
.    x 1.348 =      8992.885 :: target mean factor
.    x 1.044 =      9384.442 :: target high factor
.     x 1.31 =     12292.568 :: industry 2-weeks return factor
.    x 0.932 =     11455.358 :: "drift" penalty 4 days ago
.    x 0.977 =     11188.877 :: overall "drift" factor
.    x 0.999 =     11179.963 :: largest single-day jump factor
.     x 1.01 =     11291.626 :: mean volatility factor
.    x 1.097 =     12391.796 :: 42-day mean volatility factor
.      x 1.0 =     12389.784 :: factor hist industry gain for week 16
.   cubeRoot =         23.14 :: reduced to standardize
.    + 2.158 =        25.298 :: upcoming earnings report
.   - 21.417 =         3.881 :: add/subtract for performance
.                      3.881 :: FINAL WEIGHT for NASDAQ:ESPR


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org